Peptide Receptor Radionuclide Therapy (PRRT) in Radioiodine-Refractory Thyroid Cancer. A Case Report of Significant Response to 177Lu-Dotatate Treatment

被引：0
|
作者：
Ataei, S. [1 ]
Aryiana, K. [1 ]
Mostafavi, S. [1 ]
Esmatinia, M. [1 ]
Kosari, H. Mohammad Zadeh [1 ]
Aghaei, A. [1 ]
机构：
[1] Mashhad Univ Med Sci, Mashhad, Razavi Khorasan, Iran
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0417
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [1] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment
    Ataei-Nakhaei, Saeideh
    Aryana, Kamran
    Mostafavi, Sayyed Mostafa
    Kosari, Hadis Mohammadzadeh
    Esmatinia, Mohammad
    Aghaee, Atena
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (02):
  • [2] Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment (vol 66, pg 269, 2022)
    Mottaghi, Mahdi
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2022, 66 (04): : 587 - 587
  • [3] 177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience
    Roll, Wolfgang
    Riemann, Burkhard
    Schaefers, Michael
    Stegger, Lars
    Vrachimis, Alexis
    [J]. CLINICAL NUCLEAR MEDICINE, 2018, 43 (10) : E346 - E351
  • [4] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [5] Peptide receptor radionuclide therapy in radioiodine refractory thyroid cancer: A case report of significant response to lu177 DOTA TATE treatment
    Aghaee, A.
    Nakhaei, S. Ataei
    Aryana, K.
    Mostafavi, S.
    Kosari, H. Mohammadzadeh
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S10 - S11
  • [6] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Alfredo Campennì
    Salvatore A. Pignata
    Sergio Baldari
    [J]. Endocrine, 2015, 50 : 516 - 518
  • [7] Towards a quality assurance for dosimetry in peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
    Marin, G.
    Vanderlinden, B.
    Wimana, Z.
    Guiot, T.
    Karfis, I.
    Flamen, P.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S159 - S160
  • [8] Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campenni, Alfredo
    Pignata, Salvatore A.
    Baldari, Sergio
    [J]. ENDOCRINE, 2015, 50 (02) : 516 - 518
  • [9] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL)
    Zovato, S.
    Kumanova, A.
    Dematte, S.
    Sansovini, M.
    Bodei, L.
    Di Sarra, D.
    Casagranda, E.
    Severi, S.
    Ambrosetti, A.
    Schiavi, F.
    Opocher, G.
    Paganelli, G.
    [J]. HORMONE AND METABOLIC RESEARCH, 2012, 44 (05) : 411 - 414
  • [10] Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
    Garkavij, M.
    Nickel, M.
    Sjogreen-Gleisner, K.
    Ljungberg, M.
    Strand, S. E.
    Ohlsson, T.
    Tennvall, J.
    [J]. NEUROENDOCRINOLOGY, 2009, 90 (01) : 113 - 113
12345